Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
- Conditions
- Interventions
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT03300427
- Locations
- 🇫🇮
Novartis Investigative Site, Turku, Finland
Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD
- Conditions
- Interventions
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT03279861
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2572
- Registration Number
- NCT03066804
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- University Medicine Greifswald
- Target Recruit Count
- 9
- Registration Number
- NCT03012763
Amlodipine Versus Valsartan for Improvement of Diastolic Dysfunction Associated With Hypertension
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 104
- Registration Number
- NCT02973035
- Locations
- 🇰🇷
Busan University Hospital, Busan, Korea, Republic of
🇰🇷Chungnam University Hospital, Daejeon, Korea, Republic of
🇰🇷Busan Baik Hospital, Busan, Korea, Republic of
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5669
- Registration Number
- NCT02924727
- Locations
- 🇬🇧
Novartis Investigative Site, Worcester, United Kingdom
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 592
- Registration Number
- NCT02884206
- Locations
- 🇬🇧
Novartis Investigative Site, Stevenage, United Kingdom
EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
- Conditions
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Duke University
- Target Recruit Count
- 365
- Registration Number
- NCT02816736
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Piedmont Heart Institute, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
The DDI Study of SP2086 and Valsartan
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02817217
- Locations
- 🇨🇳
People's Liberation Army General Hospital of Chengdu Military Region, Chengdu, Sichuan, China
The Drug-drug Interaction of SP2086 and Valsartan
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02815657
- Locations
- 🇨🇳
People's Liberation Army General Hospital of Chengdu Military Region, Chengdu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.